Jonathan Krinsky, BTIG chief market technician, joins 'Closing Bell' to discuss why he's cautious on Apple and the market ...

BTIG says a “considerable amount of our time is spent thinking and talking about” Fannie Mae (FNMA) and Freddie Mac (FMCC) because those ...

Fintel reports that on December 23, 2024, BTIG downgraded their outlook for Innovative Industrial Properties, Inc. - ...

Lennar (LEN – Research Report) received a Hold rating and price target from BTIG analyst Carl Reichardt yesterday. The company’s shares ...

BTIG said it would be cautious on Apple's ( NASDAQ: AAPL) stock heading into January 2025. Analyst Jonathan Krinsky said the market can continue to make upside progress into the year-end and see a new ...

Opendoor Technologies Inc (OPEN) stock saw a decline, ending the day at $1.66 which represents a decrease of $-0.01 or -0.60% from the prior close of $1.67. The stock opened at $1.67 and touched a low ...

Chardan Capital reissued a “neutral” rating on shares of Outlook Therapeutics in a report on Monday, December 2nd. BTIG Research cut their price target on Outlook Therapeutics from $50.00 to $9.00 and ...

BTIG analyst Julian Harrison initiated coverage of Avalo Therapeutics (AVTX) with a Buy rating and $40 price target The firm sees the company’s AVTX-009 as having best-in-class features that could ...

BTIG raised the firm’s price target on Darden (DRI) to $205 from $195 and keeps a Buy rating on the shares after its Q2 ...

Stock analysts at BTIG Research started coverage on shares of Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) in a ...

Ahead of Wednesday's Fed decision, the market has been "pre-trading" expectations for a hawkish cut, BTIG added, noting a ...